Literature DB >> 22004988

Activation of p38 signaling in the microglia in the nucleus accumbens contributes to the acquisition and maintenance of morphine-induced conditioned place preference.

Xue-Qin Zhang1, Yu Cui, Yue Cui, Yu Chen, Xiao-Dong Na, Feng-Ying Chen, Xu-Hong Wei, Yong-Yong Li, Xian-Guo Liu, Wen-Jun Xin.   

Abstract

Several lines of evidence have suggested that activated glia contributes to morphine-induced reward (conditioned place preference, CPP). Compared to well-defined roles of astrocyte in morphine CPP, the role of microglia in the nucleus accumbens (NAc) remains poorly characterized. The aim of the present study was to investigate the distinct role of microglia in morphine-induced CPP. Systemic administration of morphine (7.5 mg/kg for 5 days) induced significant preference for the morphine-paired compartment in rats, which lasted for at least 6 days after cessation of morphine treatment. Immunohistochemistry results showed that activation of p38 in the NAc microglia induced by chronic morphine treatment maintained on day 11. Bilateral intra-NAc injection of minocycline, a putative microglia inhibitor, or SB203580, an inhibitor of p38, prior to morphine administration not only inhibited p38 activation in the microglia but impaired the acquisition of CPP. On the day following the acquisition of morphine CPP, a single injection of minocycline or SB203580 failed to block the expression of CPP. Notably, pretreatment with minocycline or SB203580 for 5 days following the acquisition of morphine CPP significantly suppressed the activation of p38 and attenuated the maintenance of morphine CPP. Collectively, our present study indicates that the p38 signaling in the NAc microglia may play an important role in the acquisition and maintenance but not the expression of morphine CPP, and provides new evidence that microglia might be a potential target for the therapy of morphine addiction.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004988     DOI: 10.1016/j.bbi.2011.09.017

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  28 in total

Review 1.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

2.  Alcohol alters the activation of ERK1/2, a functional regulator of binge alcohol drinking in adult C57BL/6J mice.

Authors:  Abigail E Agoglia; Amanda C Sharko; Kelly E Psilos; Sarah E Holstein; Grant T Reid; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2015-02-19       Impact factor: 3.455

Review 3.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  Glial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse.

Authors:  Michael J Lacagnina; Phillip D Rivera; Staci D Bilbo
Journal:  Neuropsychopharmacology       Date:  2016-07-11       Impact factor: 7.853

5.  Interleukin-1 signaling in the basolateral amygdala is necessary for heroin-conditioned immunosuppression.

Authors:  Lee W Hutson; Christina L Lebonville; Meghan E Jones; Rita A Fuchs; Donald T Lysle
Journal:  Brain Behav Immun       Date:  2017-01-25       Impact factor: 7.217

6.  Opioid activation of toll-like receptor 4 contributes to drug reinforcement.

Authors:  M R Hutchinson; A L Northcutt; T Hiranita; X Wang; S S Lewis; J Thomas; K van Steeg; T A Kopajtic; L C Loram; C Sfregola; E Galer; N E Miles; S T Bland; J Amat; R R Rozeske; T Maslanik; T R Chapman; K A Strand; M Fleshner; R K Bachtell; A A Somogyi; H Yin; J L Katz; K C Rice; S F Maier; L R Watkins
Journal:  J Neurosci       Date:  2012-08-15       Impact factor: 6.167

Review 7.  Neuroimmune mechanisms of psychostimulant and opioid use disorders.

Authors:  Rebecca S Hofford; Scott J Russo; Drew D Kiraly
Journal:  Eur J Neurosci       Date:  2018-09-26       Impact factor: 3.386

Review 8.  Neuroimmune basis of methamphetamine toxicity.

Authors:  Jennifer M Loftis; Aaron Janowsky
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 9.  Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation.

Authors:  Catherine M Cahill; Wendy Walwyn; Anna M W Taylor; Amynah A A Pradhan; Christopher J Evans
Journal:  Trends Pharmacol Sci       Date:  2016-09-23       Impact factor: 14.819

Review 10.  Glial neuroimmune signaling in opioid reward.

Authors:  Hong Zhang; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Brain Res Bull       Date:  2019-11-29       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.